Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 16, 2013, Pages 6413-6433

  Zheng, Xiaozhang ^a   Bauer, Paul ^a   Baumeister, Timm ^a   Buckmelter, Alexandre J ^a   Caligiuri, Maureen ^a   Clodfelter, Karl H ^a   Han, Bingsong ^a   Ho, Yen Ching ^a   Kley, Nikolai ^a   Lin, Jian ^a   Reynolds, Dominic J ^a   Sharma, Geeta ^a   Smith, Chase C ^a   Wang, Zhongguo ^a   Dragovich, Peter S ^b   Gunzner Toste, Janet ^b   Liederer, Bianca M ^b   Ly, Justin ^b   O'Brien, Thomas ^b   Oh, Angela ^b   Wang, Leslie ^b   Wang, Weiru ^b   Xiao, Yang ^b   Zak, Mark ^b   Zhao, Guiling ^b   Yuen, Po Wai ^c   Bair, Kenneth W ^a   more..

^a Forma Therapeutics   (United States)

^b GENENTECH INC   (United States)

^c Pharmaron Beijing Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HCT116; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MDCK CELL; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; DRUG DISCOVERY; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84883140710     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4008664     Document Type: Article

References (33)

1. Belenky, P.; Bogan, K. L.; Brenner, C. NAD+ metabolism in health and disease Trends Biochem. Sci. 2007, 32, 12-19
2. Koppenol, W. H.; Bounds, P. L.; Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism Nat. Rev. Cancer 2011, 11, 325-337
3. Ward, P. S.; Thompson, C. B. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate Cancer Cell 2012, 21, 297-308
4. Galli, M.; Van Gool, F.; Rongvaux, A.; Andris, F.; Leo, O. The nicotinamide phosphoribosyltransferase: A molecular link between metabolism, inflammation, and cancer Cancer Res. 2010, 70, 8-11
5. Revollo, J. R.; Grimm, A. A.; Imai, S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells J. Biol. Chem. 2004, 279, 50754-50763
6. Garten, A.; Petzold, S.; Korner, A.; Imai, S.-I.; Kiess, W. Nampt: Linking NAD Biology, Metabolism and Cancer Trends Endocrinol. Metab. 2009, 20, 130-138
7. Burgos, E. S.; Schramm, V. L. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase Biochemistry 2008, 47, 11086-11096
8. Zaremba, T.; Ketzer, P.; Cole, M.; Coulthard, S.; Plummer, E. R.; Curtin, N. J. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines Br. J. Cancer 2009, 101, 256-262
9. Khan, J. A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery Expert Opin. Ther. Targets 2007, 11, 695-705
10. Cerna, D.; Li, H.; Flaherty, S.; Takebe, N.; Coleman, C. N.; Yoo, S. S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by the small molecule GMX1778 regulates ROS-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner J. Biol. Chem. 2012, 287, 22408-22417
11. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009, 324, 1029-1033
12. Schou, C.; Ottosen, E. R.; Petersen, H. J.; Bjorkling, F.; Latini, S.; Hjarnaa, P. V.; Bramm, E.; Binderup, L. Novel cyanoguanidines with potent oral antitumor activity Bioorg. Med. Chem. Lett. 1997, 7, 3095-3100
13. Biedermann, E.; Hasmann, M.; Loser, R.; Rattel, B.; Reiter, F.; Schein, B.; Seibel, K.; Vogt, K. Preparation and formulation of pyridine derivatives as antitumor agents and immunosuppressants. WO 199748397, 1997.
14. Ravaud, A.; Cerny, T.; Terret, C.; Wanders, J.; Bui, B. N.; Hess, D.; Droz, J.-P.; Fumoleau, P.; Twelves, C. Phase I study and pharmacokinetics of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study Eur. J. Cancer 2005, 41, 702-707
15. Hovstadium, P.; Larsson, R.; Jonsson, E.; Skov, T.; Kissmeyer, A.-M.; Krasilnikoff, K.; Bergh, J.; Karlsson, M. O.; Lonnebo, A.; Ahlgren, J. A phase I study of CHS 828 in patients with solid tumor malignancy Clin. Cancer Res. 2002, 8, 2843-2850
16. Vig Hjarnaa, P.-J.; Jonsson, E.; Latini, S.; Dhar, S.; Larsson, R.; Bramm, E.; Skov, T.; Binderup, L. CHS828, a novel pyridine cyanoguanidine with potent antitumor activity in vitro and in vivo Cancer Res. 1999, 59, 5751-5757
17. Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A.-R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Invest. New Drugs 2008, 26, 45-51
18. Olesen, U. H.; Thougaard, A. V.; Jensen, P. B.; Sehested, M. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor Mol. Cancer Ther. 2010, 9, 1609-1617
19. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y.-C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P.-w.; Bair, K. W. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors J. Med. Chem. 2013, 56, 4921-4937
20. Gunzner-Toste, J.; Zhao, G.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiurib, M.; Clodfelter, K. H.; Fu, B.; Han, B.; Ho, Y.-C.; Kley, N.; Liang, X.; Liederer, B.; Lin, J.; Mukadam, S.; O'Brien, T.; Reynolds, D. J.; Sharma, G.; Skelton, N.; Smith, C. C.; Wang, W.; Wang, Z.; Xiao, Y.; Yuen, P.-w.; Zak, M.; Zhang, L.; Zheng, X.; Bair, K. W.; Dragovich, P. S. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties Bioorg. Med. Chem. Lett. 2013, 23, 3531-3538
21. For a recent and broad review of many different classes of Nampt inhibitors, see: Galli, U.; Travelli, C.; Massarotti, A.; Fakhfouri, G.; Rahimian, R.; Tron, G. C.; Genazzani, A. A. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. DOI: 10.1021/jm4001049.
22. Related PRPP adducts have also been described for other Nampt inhibitors. See: Watson, M.; Roulston, A.; Belec, L.; Billot, X.; Marcellus, R.; Bedard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; Gilbert, K.; Goulet, D.; Gratton, M. O.; Isakau, H.; Jang, A.; Khadir, A.; Koch, E.; Lavoie, M.; Lawless, M.; Nguyen, M.; Paquette, D.; Turcotte, E.; Berger, A. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol. Cell. Biol. 2009, 29, 5872-5888
23. As described in this work, compound 8 (a close structural isomer of compound 7) was observed by mass spectrometry to form PRPP-derived adducts in biochemical experiments. Compound 58 also forms an adduct with PRPP, as evidenced by mass spectrometry analysis of biochemical inhibition reaction mixtures, and we recently solved a crystal structure of phosphoribosylated- 58 in complex with Nampt. The details associated with the biochemical and crystallography experiments involving the PRPP-derived phosphoribosylated adduct of compound 58 will be reported in a separate disclosure: Oh, A.; Ho, Y.-C.; Zak, M.; Liu, Y.; Liu, Y.; Yuen, P.-w.; Zheng, X.; Dragovich, P. S.; Wang, W. manuscript in preparation.
24. Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents Nat. Struct. Mol. Biol. 2006, 13, 582-588
25. Kim, M. K.; Lee, J. H.; Kim, H.; Park, S. J.; Kim, S. H.; Kang, G. B.; Lee, Y. S.; Kim, J. B.; Kim, K. K.; Suh, S. W; Eom, S. H. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866 J. Mol. Biol. 2006, 362, 66-77
26. Wang, T.; Zhang, X.; Bheda, P.; Revollo, J. R.; Imai, S.; Wolberger, C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme Nat. Struct. Mol. Biol. 2006, 13, 661-662
27. Burgos, E. S.; Ho, M. C.; Almo, S. C.; Schramm, V. L. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13748-13753
28. Compound 58 also exhibited robust efficacy in xenograft models derived from the other cell lines listed in Table 6. Detailed descriptions of these efficacy assessments and associated PD effects will be presented elsewhere: O'Brien, T.; Xiao, Y.; Oeh, J.; Liang, X.; Vanderbilt, A.; Qin, A.; Yang, L.; Lee, L. B.; Ly, J.; Cosino, E.; LaCap, J. A.; Ogasawara, A.; Nannini, M.; Liederer, B. M.; Jackson, P.; Williams, S.; Dragovich, P. S.; Sampath, D. Submitted to Cancer Res.
29. Sikazwe, D.; Bondarev, M. L.; Dukat, M.; Rangisetty, J. B.; Roth, B. L.; Glennon, R. A. Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors J. Med. Chem. 2006, 49, 5217-5225
30. Thurkauf, A.; Chen, D.; Phadke, A.; Li, S.; Deshpande, M. Preparation of azabenzofuran substituted thioureas as inhibitors of viral replication. WO 2005067900, 2005.
31. Li, Q.; Woods, K. W.; Claiborne, A.; Gwaltney, S. L., II; Barr, K. J.; Liu, G.; Gehrke, L.; Credo, R. B.; Hui, Y. H.; Lee, J.; Warner, R. B.; Kovar, P.; Nukkala, M. A.; Zielinski, N. A.; Tahir, S. K.; Fitzgerald, M.; Kim, K. H.; Marsh, K.; Frost, D.; Ng, S.; Rosenberg, S.; Sham, H. L. Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent Bioorg. Med. Chem. Lett. 2002, 12, 465-469
32. Fyfe, M. C. T.; Thomas, G. H.; Gardner, L. S.; Bradley, S. E.; Gattrell, W.; Rasamison, C. M.; Shah., V. K. Preparation of furopyridine and pyrrolopyridine derivatives and analogs thereof as G-protein coupled receptor agonists. WO 2006067532, 2006.
33. Walker, D. P.; Piotrowski, D. W.; Jacobsen, E. J.; Acker, B. A.; Wishka, D. G.; Reitz, S. C.; Groppi, V. E., Jr. Preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists. WO 2003029252, 2003.